NR1I2 and prostate cancer: Furthermore, PXR knockdown using shRNA constructs enhanced the chemosensitivity of prostate cancer cells to chemotherapeutic drugs, suggesting a contributing role of PXR to chemoresistance in prostate cancer[32].